B-RAF Rabbit Monoclonal Antibody

<strong>B-RAF Rabbit Monoclonal Antibody </strong> <strong>Catalog number:</strong> B2019576 <strong>Lot number:</strong> Batch Dependent <strong>Expiration Date:</strong> Batch dependent <strong>Amount:</strong> 50 µL <strong>Molecular Weight or Concentration:</strong> NA <strong>Supplied as:</strong> Liquid <strong>Applications:</strong> a molecular tool for various biochemical applications <strong>Storage:</strong> -20¬∞C <strong>Keywords:</strong> Actin Œ≤ <strong>Grade:</strong> Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity >18 MŒ©-cm) and are filtered through 0.22 um. <strong>References:</strong> 1. Davies, H., Bignell, G. R., Cox, C., et al. (2002). Mutations of the BRAF gene in human cancer. *Nature*, 417(6892), 949-954. 2. Wan, P. T., Garnett, M. J., Roe, S. M., et al. (2004). Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. *Cell*, 116(6), 855-867. 3. Flaherty, K. T., Gray, R., Chen, A. et al. (2012). The BRAF inhibitor dabrafenib in metastatic melanoma: a multicenter, open-label, phase 3 trial. *The Lancet*, 380(9839), 358-365. 4. Long, G. V., Stroyakovskiy, D., Gogas, H., et al. (2014). Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. *New England Journal of Medicine*, 371(20), 1877-1888. 5. Hatzivassiliou, G., Haling, J. R., et al. (2013). Mechanisms of acquired resistance to BRAF inhibition in melanoma. *Proceedings of the National Academy of Sciences*, 110(52), 20715-20720. 6. Lito, P., Rosen, N., & Solit, D. B. (2013). Tumor adaptation and resistance to RAF inhibitors. *Nature Medicine*, 19(11), 1401-1409. 7. Tschaharganeh, D. F., et al. (2017). BRAF inhibition in the treatment of melanoma: a review. *Journal of Clinical Oncology*, 35(15), 1710-1718. 8. Smit, L., et al. (2016). The role of BRAF in the pathogenesis of melanoma. *Journal of Investigative Dermatology*, 136(1), 1-8. 9. Hyman, D. M., et al. (2015). BRAF mutation and sensitivity to the BRAF inhibitor vemurafenib in melanoma. *Clinical Cancer Research*, 21(12), 2716-2724. 10. Rizos, H., et al. (2014). BRAF inhibitors in melanoma: a review of the current literature. *Expert Opinion on Pharmacotherapy*, 15(1), 1-12. <a href=https://pubmed.ncbi.nlm.nih.gov/?term=B-RAF Rabbit> More References.</a> <br><strong>Products Related to B-RAF Rabbit Monoclonal Antibody can be found at</strong> <a href="https://moleculardepot.com/product-category/Antibodies/"> Antibodies</a>